Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment

by Elena Iemma | May 19, 2025 | Blog

FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

by Elena Iemma | Feb 27, 2025 | News

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

by Elena Iemma | Oct 24, 2024 | News

PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...

Immunogenicity Risk Assessment: In Silico, In Vitro, and What’s Next

by Elena Iemma | Aug 18, 2024 | Blog

Immunogenicity Risk Assessment: In Silico, In Vitro, and What’s Next Don’t Miss This one! Put this one on your calendar: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk … The gang will all be...

FDA Request for “Integrated Summary of Immunogenicity”

by Elena Iemma | Dec 23, 2023 | Blog

FDA Request for “Integrated Summary of Immunogenicity” So much news to share!  EpiVax Delivers! As promised, EpiVax 2.0 will be arriving in 2024, our 26th year, along with new team members and new plans to expand the range of services offered. Here...